This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
VERAXA Biotech (VRXA) receives Scientific Advice from Germany's Paul-Ehrlich-Institute on its dual-targeting BiTAC-TCE cancer therapy, with preclinical data showing selective tumor targeting and a favorable safety profile. A key step toward clinical development. #Biotech #Oncology
2026-07-20T23:01:23.768Z